DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

Molecular Testing for the Management of Pancreatic Cysts and Solid Pancreaticobiliary Lesions

Defines coverage and prior authorization expectations for the PathfinderTG/PancraGEN laboratory-developed molecular test for management of pancreatic cysts and solid pancreaticobiliary lesions for BCBSRI Medicare Advantage and Commercial products.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMolecular Testing for the Management of Pancreatic Cysts and Solid Pancreaticobiliary Lesions

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date01 01 2026

Next Review DateN/A

Key ActionObtain prior authorization (ordering physician only) for Medicare Advantage Plans and for commercial products as recommended; unlisted CPT codes require authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

35publications identified

4publications on current version

97%Benign category 3-yr prob

91%Aggressive category prob

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not covered / Not medically necessary

Coverage stance for PancraGEN/PathfinderTG

Coverage determination: PathfinderTG/PancraGEN molecular testing is not covered for Medicare Advantage Plans and is considered not medically necessary for Commercial Products due to insufficient evidence of clinical validity and clinical utility.

Policy notes lack of prospective studies, incomplete assessment of the current test version (e.g., missing assessment of GNAS and other alterations in many studies), and insufficient evidence that testing affects patient management or outcomes.

Some genetic test services may be contractually excluded for self-funded groups under the state Biomarker Test Mandate. Applicability of any exclusion depends on the member's Benefit Booklet and employer contract; providers should consult the member's plan documents to determine whether the expanded coverage for biomarker tests has been excluded for that group.

BCBSRI considers PancraGEN (PathfinderTG) not medically necessary for Commercial products because the available literature does not establish the test's clinical validity or clinical utility. The current PancraGEN algorithm classifies risk primarily by presence or absence of a set of molecular alterations, but existing studies do not fully assess all alterations in the current version of the test (for example, GNAS and clonality are not consistently evaluated), limiting statistical validity. In addition, there are no prospective studies demonstrating that PancraGEN testing changes management or improves patient outcomes, and guideline endorsement is lacking; therefore the evidence is insufficient to determine effects on health outcomes.

Covered Indications

Evaluation of pancreatic cysts or solid pancreaticobiliary lesions when first-line pathological and radiologic evaluation is inconclusive

Covered when ALL of the following are met:

Intended clinical scenario: Test ordered for evaluation of a pancreatic cyst or solid pancreaticobiliary lesion when first-line pathologic and radiologic evaluation is inconclusive.

Topographic genotyping (microdissection with molecular analysis) is the claimed intended use but evidence does not support coverage.

Specimen requirements: A tissue specimen suitable for microdissection and molecular analysis is available (including small needle biopsy specimens or archived paraffin-embedded tissue).

PathFinderTG permits analysis of minute needle biopsy specimens and archived paraffin samples.

Clinical context: Results would be used to inform management decisions only after consideration of clinical, radiologic, and pathologic findings; ordering clinicians must understand current evidence limitations and lack of guideline endorsement.

Policy highlights absence of prospective studies and potential for false reassurance from limited follow-up data.

Coding

Unlisted CPT codesCPT

84999	Unlisted chemistry procedure (used when no CPT adequately describes the service)
81479	Unlisted molecular pathology procedure

Coding threshold — 'Aggressive' category criteria

Threshold to trigger 'Aggressive' categoryPresence of 2 or more significant molecular alterations triggers the 'Aggressive' category

Defined significant alterations in sample reportExamples include high-clonality KRAS mutation, high-clonality GNAS mutation, high-clonality loss-of-heterozygosity (LOH) tumor suppressor gene mutation, and multiple low-clonality LOH mutations

Effect on risk stratification'Aggressive' category confers ~91% probability of high-grade dysplasia (HGD) or carcinoma per the sample report

Provider Actions & Billing

Prior Authorization

Prior authorization required

Prior authorization is required for Medicare Advantage Plans and is recommended for Commercial Products. Unlisted CPT codes for these tests require authorization to determine the service and coverage.

Obtain prior authorization via the online tool for participating providers.

Step Therapy

Step therapy

No step therapy is specified in this policy.

Documentation Required

Coding and documentation for unlisted CPTs

Use an appropriate unlisted CPT when no established code exists (e.g., 84999 or 81479). All unlisted genetic test CPT codes require authorization to determine the service rendered and coverage status.

Report services without an established CPT as 84999 or 81479 as applicable.
Ensure authorization documentation supports clinical appropriateness for unlisted genetic test CPT codes.

Denial Risk

Authorization and denial risk

Services provided without required authorization will be denied. Laboratories may not obtain authorization on behalf of the ordering physician; attempts to do so may result in severe action up to network termination.

If a laboratory provides a service that has not been authorized, the service will be denied and may not be billed to the member.

Ordering Requirements

Note

Ordering requirements — physician must obtain authorization

Only the ordering physician may obtain prior authorization; laboratories are prohibited from obtaining authorization or participating in the authorization or appeal process on behalf of the ordering physician.

Do not use a laboratory representative or related third party to obtain authorization, facilitate the authorization process, or prepare documentation for appeals; such actions are violations and may result in severe action including termination.

Not Covered

PathfinderTG/PancraGEN molecular testing is not covered for BCBSRI Medicare Advantage Plans and is considered not medically necessary for Commercial products. The policy concludes that the evidence is insufficient to determine clinical validity and clinical utility of the current PancraGEN version, and therefore testing will not be covered under Medicare Advantage and is not medically necessary for Commercial members.

Background

Pancreatic cysts are fluid-filled, cell-lined structures most commonly representing mucinous lesions such as intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms; these lesions carry a variable risk of progression to pancreatic cancer. Solid pancreaticobiliary lesions have a broad differential that includes primary pancreatic malignancies and benign inflammatory conditions. Topographic genotyping approaches (PathfinderTG/PancraGEN) integrate microdissection of tissue with molecular analysis to try to stratify risk when first-line radiologic and pathologic evaluation is inconclusive.

Definitions

Definition — Topographic genotyping

Topographic genotyping definitionIntegration of microscopic anatomic pathology with molecular tissue analysis using microdissection to enrich tumor cells for molecular testing

PurposeMay permit pathologic diagnosis when first-line pathologic and radiologic analyses are inconclusive

Specimen typesCan be applied to tissue specimens including minute needle biopsies and archived paraffin‑embedded specimens

Definition — PancraGEN / PathfinderTG

Test/platformPancraGEN (also known as PathfinderTG or Integrated Molecular Pathology) — a patented proprietary molecular testing platform by Interpace Diagnostics

FunctionAnalyzes mutational and other molecular markers plus cyst fluid and radiologic data to algorithmically stratify risk for pancreatic cysts and solid pancreaticobiliary lesions

Versioning and algorithm updatesThe test has undergone multiple updates to input data and algorithmic categorization; current version heavily weights molecular data in risk assignment